Rob represents public and private technology and life sciences companies, including Microchip Technology, National Instruments, RealPage, Savara and Lumos Pharma as well as investment banks and VC funds.
Rob is consistently recognized as a leader in his field by Chambers USA.
Robert Suffoletta is a partner in the corporate and securities practice of Wilson Sonsini Goodrich & Rosati. He joined the firm's Austin office in 2001 after starting his career in the firm's Palo Alto office.
Rob works with emerging growth and technology companies, both public and private, as well as investment banks and venture capital funds. During his tenure at the firm, he has gained extensive experience with public offerings, mergers and acquisitions, venture capital financings, and start-up company representation. He regularly advises a number of public companies on corporate governance, disclosure, and SEC compliance matters.
Rob is a member of the board of directors of the Wilson Sonsini Foundation.
Prior to attending law school, Rob was a financial consultant with Peterson & Company in Chicago, where he specialized in financial and economic analysis for complex commercial litigation.
Robert Suffoletta is a partner in the corporate and securities practice of Wilson Sonsini Goodrich & Rosati. He joined the firm's Austin office in 2001 after starting his career in the firm's Palo Alto office.
Rob works with emerging growth and technology companies, both public and private, as well as investment banks and venture capital funds. During his tenure at the firm, he has gained extensive experience with public offerings, mergers and acquisitions, venture capital financings, and start-up company representation. He regularly advises a number of public companies on corporate governance, disclosure, and SEC compliance matters.
Rob is a member of the board of directors of the Wilson Sonsini Foundation.
Prior to attending law school, Rob was a financial consultant with Peterson & Company in Chicago, where he specialized in financial and economic analysis for complex commercial litigation.